Estimation of systemic distribution and angiogenic effect of PL-VEGF165 in the model of limb ischemia
Автор: Yudin M.A., Plaksa I.L., Mzhavanadze N.D., Krakovskii M.A., Bykov V.N., Mavlikeev M.O., Isaev A.A., Kalinin R.E., Deev R.V.
Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin
Рубрика: Экспериментальные статьи
Статья в выпуске: 4-2 т.19, 2015 года.
Бесплатный доступ
The group of cardio-vascular diseases accompanied by ischemia is the leading cause of a death in the world. Regarding this issue, creating the novel pharmacy drugs reducing ischemia and integrating them in a routine clinical practice is pivotal. The therapeutic angiogenesis with gene therapy drugs is considered like a prospective approach at this field. The gene constructions included a gene one of the angiogenic growth factors can be used as an instrument for blood flow restoration in ischemic tissues by increasing an amount of microvascular vessels. However, there are some traditional safety precautions and concerns connected with its potential systemic effect which can cause vessels growth on the distance and lead to complications. In this paper pharmacokinetic qualities of gene construction on a base of plasmid with a gene of vascular endothelial growth factor are described. The efficiency of an angiogenic effect was estimated on animal model with chronic ischemia of lower limb.
Сосудистый эндотелиальный фактор роста vegf, gene therapy, chronical limb ischemia, vascular endothelial growth factor, vegf, plasmid, pharmacokinetics
Короткий адрес: https://sciup.org/142140715
IDR: 142140715